Astellas Pharma Global Development, Inc., a pharmaceutical company with headquarters in Tokyo, Japan, and Northbrook, Illinois, has promoted Andrew Krivoshik to vice president of medical science-oncology. He will lead the group in the therapeutic area and be responsible to advance Astellas developments in oncology, which include clinical programs. Formerly, Krivoshik was the executive medical director in the company’s oncology therapeutic area.

Earlier in his career, Krivoshik was a senior medical director at Abbott, where he completed their Physician Development Program. He has implemented novel and innovative clinical trial designs and served as a subject matter expert and primary author of clinical protocols, for example. He received his undergraduate degree in electrical engineering from Princeton in 1990, followed by a medical degree from the University of Illinois College of Medicine at Urbana-Champaign. His clinical internship and residency were at the Mayo Clinic, and his fellowship training was at Duke University. Krivoshik is licensed as both a physician and engineer.